Award-Winning CRO NJ Bio, Inc. has been recognized as the Best Contract Research Organization at the World ADC Summit for three consecutive years, highlighting its strong reputation and potential for attracting high-value biotech and pharma clients seeking trusted CRO services for ADC development.

Strategic Partnerships Collaborations with Lotte Biologics and a focus on bioconjugation processes present opportunities to offer advanced ADC process development and manufacturing solutions, especially for clients seeking integrated bioconjugation and ADC services.

Technological Innovation NJ Bio's ongoing development of platform BioNMR solutions and utilization of cutting-edge tools like 800 MHz NMR indicates a capability to support clients with sophisticated analytical and process development requirements, opening channels for high-end analytical service sales.

Growth and Expansion With a revenue range between $50 million and $100 million and recent expansions in clinical and manufacturing facilities, NJ Bio presents a lucrative opportunity for sales of scalable biologics, process development services, and GMP manufacturing contracts.

Global Presence Having subsidiaries in India and facilities in the US, NJ Bio's international footprint allows for cross-border service offerings in bioconjugation, ADC production, and biopharma research, enabling tailored solutions to multinational biotech clients seeking comprehensive CRO support.